Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1061900 | 1.00 | CHRM2 (0.34) | CHRM2CHRM1ALDH1A1MAPTMAPK1 | |
| SCHEMBL348916 | 0.94 | CHRM2 (0.42) | CHRM2CHRM1ALDH1A1MAPTMAPK1 | |
| Hydrochloric Acid SCHEMBL310122 | 0.92 | CHRM2 (0.41) | CHRM2CHRM1ALDH1A1MAPTMAPK1 | |
| SCHEMBL25625929 | 0.85 | DAO (0.41) | CHRM2CHRM1ALDH1A1MAPTMAPK1 | |
| SCHEMBL1005285 | 0.84 | CHRM2 (0.35) | CHRM2CHRM1ALDH1A1MAPTMAPK1 | |
| SCHEMBL64211 | 0.84 | CHRM2 (0.47) | CHRM2CHRM1ALDH1A1MAPTHTT | |
| SCHEMBL3178617 | 0.82 | CHRM2 (0.46) | CHRM2CHRM1ALDH1A1MAPTHTT | |
| SCHEMBL22345800 | 0.82 | CHRM2 (0.46) | CHRM2CHRM1ALDH1A1MAPTHTT | |
| SCHEMBL6261605 | 0.81 | POLB (0.32) | NPSR1 | |
| SCHEMBL63679 | 0.80 | PTGS1 (0.39) | ALDH1A1MAPTMAPK1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013118953-A1 | METHOD FOR THE FIXATION OR CONVERSION OF HIGH-PRESSURE CARBON DIOXIDE USING BAROPHILIC SULFUR-OXIDIZING CHEMOLITHOAUTOTROPHS | 연세대학교 산학협력단 (KR) | 2013-08-15 | — | — | WO | claimed |
| US-20120149868-A1 | PURIFICATION OF PEPTIDES PREPARED BY SOLID PHASE SYNTHESIS | NOVO NORDISK A/S (DK) | 2012-06-14 | — | — | US | claimed |
| WO-2017111458-A1 | APPARATUS FOR IMMOBILIZING MICROBIAL CELLS AND METHOD FOR IMMOBILIZING MICROBIAL CELLS USING SAME | 대상 주식회사 | 2017-06-29 | — | — | WO | disclosed |
| WO-2015099246-A1 | ENSIFER SP. STRAIN AND METHOD FOR PRODUCING PSICOSE USING SAME | 주식회사 삼양제넥스 | 2015-07-02 | — | — | WO | disclosed |
| WO-2014119725-A1 | METHOD FOR REDUCING FALSE NEGATIVES IN IMMUNOASSAY FOR ASSAYING BIOMEMBRANE-DERIVED SPECIMEN | デンカ生研株式会社 (JP) | 2014-08-07 | — | — | WO | disclosed |
| WO-2013118953-A1 | METHOD FOR THE FIXATION OR CONVERSION OF HIGH-PRESSURE CARBON DIOXIDE USING BAROPHILIC SULFUR-OXIDIZING CHEMOLITHOAUTOTROPHS | 연세대학교 산학협력단 (KR) | 2013-08-15 | — | — | WO | disclosed |
| WO-2013027999-A9 | D-PSICOSE 3-EPIMERASE MUTANT WITH IMPROVED THERMAL STABILITY, AND CONTINUOUS PRODUCTION OF D-PSICOSE USING SAME | 씨제이제일제당(주) (KR) | 2013-07-11 | — | — | WO | disclosed |
| WO-2013027999-A2 | D-PSICOSE 3-EPIMERASE MUTANT WITH IMPROVED THERMAL STABILITY, AND CONTINUOUS PRODUCTION OF D-PSICOSE USING SAME | 씨제이제일제당(주) (KR) | 2013-02-28 | — | — | WO | disclosed |
| US-20120149868-A1 | PURIFICATION OF PEPTIDES PREPARED BY SOLID PHASE SYNTHESIS | NOVO NORDISK A/S (DK) | 2012-06-14 | — | — | US | disclosed |
| WO-2011049409-A9 | MANNOSE 6-PHOSPHATE ISOMERASE, MUTANTS THEREOF, AND USE THEREOF | 건국대학교 산학협력단 (KR) | 2011-09-15 | — | — | WO | disclosed |
| WO-2011049409-A2 | MANNOSE 6-PHOSPHATE ISOMERASE, MUTANTS THEREOF, AND USE THEREOF | 건국대학교 산학협력단 (KR) | 2011-04-28 | — | — | WO | disclosed |
| US-20040132207-A1 | Method for stabilizing blood, serum, or plasma specimen and container containing pH buffer agent | KYOKUTO PHARMACEUTICAL INDUSTRIAL CO. LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
| EP-1391209-A1 | PROTEIN FORMULATIONS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-02-25 | — | — | EP | disclosed |
| US-20010025791-A1 | Methods and devices for separation of biological molecules | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2001-10-04 | — | — | US | disclosed |
| US-5554590-A | Method of treating asthma | EAST CAROLINA UNIVERSITY (US) | 1996-09-10 | — | — | US | disclosed |
| US-5538846-A | DIAGNOSIS OF LEUKEMIA, DETECTING TRANSLOCATION | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 1996-07-23 | — | — | US | disclosed |
| US-5081028-A | Gene expession; antiallergens | CIBA-GEIGY CORPORATION (US) | 1992-01-14 | — | — | US | disclosed |
| US-4743553-A | Synthetic genes for bovine parainfluenza virus | W. R. GRACE & CO. (US) | 1988-05-10 | — | — | US | disclosed |
| EP-0208518-A2 | 6-Phenyl-pyridazinyl compounds | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1987-01-14 | — | — | EP | disclosed |
| EP-0201988-A2 | Dihydropyridazinone derivatives | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1986-11-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149868-A1 | PURIFICATION OF PEPTIDES PREPARED BY SOLID PHASE SYNTHESIS | VIP, IAPP, NGLY1 | CHRM2 4849/4885CHRM1 4868/4885ALDH1A1 4607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.